arrow_back Trending Legislation
Share share

Study to streamline access to cheaper interchangeable biosimilar drugs

This law requires the Department of Health to conduct a detailed study on the process of designating biosimilar biological products as interchangeable. The goal is to understand the challenges and data required for this status. Streamlining access to interchangeable biosimilars could increase market competition, potentially resulting in lower treatment costs for citizens.
Key points
Mandates the FDA to conduct a study on how biosimilar drugs achieve "interchangeable" status.
The report must assess the data needed for approval and the challenges faced by manufacturers.
Increased approval of interchangeable biosimilars could lead to lower prices for expensive biological medicines.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.
Print number: S 1522
Sponsor: Sen. Marshall, Roger [R-KS]
Process start date: 2023-05-10
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Study to streamline access to cheaper interchangeable biosimilar drugs

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1522.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-05-10.

What are the main provisions?

Key points include:

  • Mandates the FDA to conduct a study on how biosimilar drugs achieve "interchangeable" status.
  • The report must assess the data needed for approval and the challenges faced by manufacturers.
  • Increased approval of interchangeable biosimilars could lead to lower prices for expensive biological medicines.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Marshall, Roger [R-KS].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Analysis and Potential Impact of S 1522

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health